Russia: Egypt Will Produces The Sputnik V Vaccine

The Russian Direct Investment Fund, which markets anti-virus vaccines abroad, said today, Thursday, that the Egyptian company, MinaPharm has agreed to produce more than 40 million doses of the Russian Sputnik v vaccine annually.

The fund added, in a joint statement with Minapharm, that the two parties agreed to start transferring technology immediately, and production is expected to start in the third quarter of this year.

The Russian Direct Investments Fund confirmed in a statement issued today, Thursday, that the contract it concluded with the Egyptian company Minapharm and its subsidiary ProBioGen, based in Germany, requires the production of more than 40 million doses of the Russian vaccine in Egypt annually in the first phase.